Clinical variation in X-linked adrenoleukodystrophy

Fatty acid and lipid metabolism in cultured fibroblasts

Debra J. Boles, Debra A. Craft, David A. Padgett, Roger M. Loria, William B Rizzo

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

To determine whether the clinical phenotype of ALD correlates with the extent of metabolic abnormality, we investigated VLFA metabolism in cultured fibroblasts from patients with the clinically severe childhood form of ALD and the milder AMN variant. No differences were seen in the content of neutral lipids or phospholipids, in incorporation of [1-14C]lignocerate into cellular lipids, or in the fatty acid composition of fibroblasts from patients with childhood ALD or AMN. [1-14C]Lignocerate oxidation was deficient to a similar extent (35-40% of normal) in both intact fibroblasts and cell homogenates from patients with childhood ALD and AMN. With the use of fibroblast homogenates, oxidation of lignocerate was partially inhibited by various long-chain fatty acids, and residual activity in ALD homogenates was more susceptible to inhibition by palmitate than normal. In the presence of competing palmitate, residual lignocerate oxidative activity in fibroblast homogenates was reduced to 20 ± 4% of normal in childhood ALD and 24 ± 2% of normal in AMN. These results indicate that residual VLFA oxidative activity, fatty acid composition, VLFA metabolism, and lipid content of cultured fibroblasts do not correlate with the clinical expression of the ALD gene.

Original languageEnglish (US)
Pages (from-to)74-91
Number of pages18
JournalBiochemical Medicine and Metabolic Biology
Volume45
Issue number1
DOIs
StatePublished - Jan 1 1991

Fingerprint

Adrenoleukodystrophy
Fibroblasts
Lipid Metabolism
Fatty Acids
Palmitates
Lipids
Metabolism
Oxidation
Chemical analysis
Phospholipids
Genes
Phenotype
Gene Expression

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry

Cite this

Clinical variation in X-linked adrenoleukodystrophy : Fatty acid and lipid metabolism in cultured fibroblasts. / Boles, Debra J.; Craft, Debra A.; Padgett, David A.; Loria, Roger M.; Rizzo, William B.

In: Biochemical Medicine and Metabolic Biology, Vol. 45, No. 1, 01.01.1991, p. 74-91.

Research output: Contribution to journalArticle

Boles, Debra J. ; Craft, Debra A. ; Padgett, David A. ; Loria, Roger M. ; Rizzo, William B. / Clinical variation in X-linked adrenoleukodystrophy : Fatty acid and lipid metabolism in cultured fibroblasts. In: Biochemical Medicine and Metabolic Biology. 1991 ; Vol. 45, No. 1. pp. 74-91.
@article{4bc7ce50891c4a5cb31c8a06adc2403f,
title = "Clinical variation in X-linked adrenoleukodystrophy: Fatty acid and lipid metabolism in cultured fibroblasts",
abstract = "To determine whether the clinical phenotype of ALD correlates with the extent of metabolic abnormality, we investigated VLFA metabolism in cultured fibroblasts from patients with the clinically severe childhood form of ALD and the milder AMN variant. No differences were seen in the content of neutral lipids or phospholipids, in incorporation of [1-14C]lignocerate into cellular lipids, or in the fatty acid composition of fibroblasts from patients with childhood ALD or AMN. [1-14C]Lignocerate oxidation was deficient to a similar extent (35-40{\%} of normal) in both intact fibroblasts and cell homogenates from patients with childhood ALD and AMN. With the use of fibroblast homogenates, oxidation of lignocerate was partially inhibited by various long-chain fatty acids, and residual activity in ALD homogenates was more susceptible to inhibition by palmitate than normal. In the presence of competing palmitate, residual lignocerate oxidative activity in fibroblast homogenates was reduced to 20 ± 4{\%} of normal in childhood ALD and 24 ± 2{\%} of normal in AMN. These results indicate that residual VLFA oxidative activity, fatty acid composition, VLFA metabolism, and lipid content of cultured fibroblasts do not correlate with the clinical expression of the ALD gene.",
author = "Boles, {Debra J.} and Craft, {Debra A.} and Padgett, {David A.} and Loria, {Roger M.} and Rizzo, {William B}",
year = "1991",
month = "1",
day = "1",
doi = "10.1016/0885-4505(91)90010-I",
language = "English (US)",
volume = "45",
pages = "74--91",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Clinical variation in X-linked adrenoleukodystrophy

T2 - Fatty acid and lipid metabolism in cultured fibroblasts

AU - Boles, Debra J.

AU - Craft, Debra A.

AU - Padgett, David A.

AU - Loria, Roger M.

AU - Rizzo, William B

PY - 1991/1/1

Y1 - 1991/1/1

N2 - To determine whether the clinical phenotype of ALD correlates with the extent of metabolic abnormality, we investigated VLFA metabolism in cultured fibroblasts from patients with the clinically severe childhood form of ALD and the milder AMN variant. No differences were seen in the content of neutral lipids or phospholipids, in incorporation of [1-14C]lignocerate into cellular lipids, or in the fatty acid composition of fibroblasts from patients with childhood ALD or AMN. [1-14C]Lignocerate oxidation was deficient to a similar extent (35-40% of normal) in both intact fibroblasts and cell homogenates from patients with childhood ALD and AMN. With the use of fibroblast homogenates, oxidation of lignocerate was partially inhibited by various long-chain fatty acids, and residual activity in ALD homogenates was more susceptible to inhibition by palmitate than normal. In the presence of competing palmitate, residual lignocerate oxidative activity in fibroblast homogenates was reduced to 20 ± 4% of normal in childhood ALD and 24 ± 2% of normal in AMN. These results indicate that residual VLFA oxidative activity, fatty acid composition, VLFA metabolism, and lipid content of cultured fibroblasts do not correlate with the clinical expression of the ALD gene.

AB - To determine whether the clinical phenotype of ALD correlates with the extent of metabolic abnormality, we investigated VLFA metabolism in cultured fibroblasts from patients with the clinically severe childhood form of ALD and the milder AMN variant. No differences were seen in the content of neutral lipids or phospholipids, in incorporation of [1-14C]lignocerate into cellular lipids, or in the fatty acid composition of fibroblasts from patients with childhood ALD or AMN. [1-14C]Lignocerate oxidation was deficient to a similar extent (35-40% of normal) in both intact fibroblasts and cell homogenates from patients with childhood ALD and AMN. With the use of fibroblast homogenates, oxidation of lignocerate was partially inhibited by various long-chain fatty acids, and residual activity in ALD homogenates was more susceptible to inhibition by palmitate than normal. In the presence of competing palmitate, residual lignocerate oxidative activity in fibroblast homogenates was reduced to 20 ± 4% of normal in childhood ALD and 24 ± 2% of normal in AMN. These results indicate that residual VLFA oxidative activity, fatty acid composition, VLFA metabolism, and lipid content of cultured fibroblasts do not correlate with the clinical expression of the ALD gene.

UR - http://www.scopus.com/inward/record.url?scp=0025980226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025980226&partnerID=8YFLogxK

U2 - 10.1016/0885-4505(91)90010-I

DO - 10.1016/0885-4505(91)90010-I

M3 - Article

VL - 45

SP - 74

EP - 91

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 1

ER -